8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Mar 31, 2026·SEC
Barinthus Biotherapeutics plc(BRNS)Earnings, Financials & Key Ratios
BRNS•NASDAQ
$0.64
$26M mkt cap·Price updated May 6, 2026
AboutBarinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.Show more
- Revenue$0-100.0%
- EBITDA-$48M+22.2%
- Net Income-$66M-8.8%
- EPS (Diluted)-1.64-5.8%
- ROE-64.99%-68.7%
- ROIC-174.46%-52.9%
- Debt/Equity0.15+64.6%
- Interest Coverage-1060.16+8.1%
BRNS Key Insights
Barinthus Biotherapeutics plc (BRNS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 30.3% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BRNS Price & Volume
Barinthus Biotherapeutics plc (BRNS) stock price & volume — 10-year historical chart
Loading chart...
BRNS Growth Metrics
Barinthus Biotherapeutics plc (BRNS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM21.34%
Return on Capital
10 Years-59.57%
5 Years-30.55%
3 Years-40.76%
Last Year-46.55%
BRNS Peer Comparison
Barinthus Biotherapeutics plc (BRNS) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 IMCR | 1.56B | 30.73 | -57.98 | 20% | -4.88% | -4.83% | 0.11 | |
 ADCT | 490.96M | 3.86 | -3.45 | 14.85% | -173.02% | |||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 |
Compare BRNS vs Peers
Barinthus Biotherapeutics plc (BRNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRNS Income Statement
Barinthus Biotherapeutics plc (BRNS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.85M | 4.82M | 268K | 44.7M | 802K | 14.97M | 0 | 0 |
| Revenue Growth % | - | -29.57% | -94.44% | 16580.22% | -98.21% | 1766.46% | -100% | -100% |
| Cost of Goods Sold | 29.84M | 14.39M | 0 | 0 | 0 | 0 | 5.86M | 907.69K |
| COGS % of Revenue | 435.97% | 298.42% | - | - | - | - | - | - |
| Gross Profit | -23M▲ 0% | -9.57M▲ 58.4% | 268K▲ 102.8% | 44.7M▲ 16580.2% | 802K▼ 98.2% | 14.97M▲ 1766.5% | -5.86M▼ 139.1% | -907.69K▲ 0% |
| Gross Margin % | -335.97% | -198.42% | 100% | 100% | 100% | 100% | - | - |
| Gross Profit Growth % | - | 58.4% | 102.8% | 16580.22% | -98.21% | 1766.46% | -139.14% | - |
| Operating Expenses | 2.67M | 10.48M | 45.49M | 48.74M | 84.72M | 82.94M | 48.34M | 56.08M |
| OpEx % of Revenue | 38.97% | 217.38% | 16973.51% | 109.04% | 10563.09% | 554.07% | - | - |
| Selling, General & Admin | 2.67M | 10.48M | 25.12M | 6.39M | 39.84M | 29.67M | 40.83M | 30.72M |
| SG&A % of Revenue | 38.97% | 217.38% | 9372.39% | 14.3% | 4967.83% | 198.21% | - | - |
| Research & Development | 29.84M | 14.39M | 16.37M | 41.11M | 41.41M | 38.25M | 25.56M | 19.29M |
| R&D % of Revenue | 435.97% | 298.42% | 6108.21% | 91.96% | 5163.72% | 255.55% | - | - |
| Other Operating Expenses | -29.84M | -14.39M | 4M | 1.24M | 3.46M | 15.02M | -18.06M | 1.99M |
| Operating Income | -25.66M▲ 0% | -20.05M▲ 21.9% | -45.22M▼ 125.6% | -4.04M▲ 91.1% | -83.91M▼ 1976.6% | -67.97M▲ 19.0% | -54.19M▲ 20.3% | -39.67M▲ 0% |
| Operating Margin % | -374.94% | -415.81% | -16873.51% | -9.04% | -10463.09% | -454.07% | - | - |
| Operating Income Growth % | - | 21.89% | -125.59% | 91.06% | -1976.57% | 19% | 20.27% | - |
| EBITDA | -25.5M | -19.84M | -44.62M | 282K | -78.48M | -62.17M | -48.35M | -35.56M |
| EBITDA Margin % | -372.49% | -411.49% | -16648.88% | 0.63% | -9786.16% | -415.32% | - | - |
| EBITDA Growth % | - | 22.19% | -124.92% | 100.63% | -27931.56% | 20.79% | 22.23% | 45.5% |
| D&A (Non-Cash Add-back) | 167.62K | 208K | 602K | 4.32M | 5.43M | 5.8M | 5.84M | 4.11M |
| EBIT | -22.69M | -16.77M | -48.47M | 869K | -76.49M | -61.17M | -54.19M | -45.18M |
| Net Interest Income | -92.93K | -3.6M | -2.67M | 3.08M | 2.85M | 2.63M | 1.91M | 1.36M |
| Interest Income | 40.37K | 0 | 2K | 3.1M | 2.88M | 2.68M | 1.96M | 1.75M |
| Interest Expense | 133.3K | 3.6M | 2.67M | 19K | 28K | 53K | 51.12K | 24.98K |
| Other Income/Expense | 2.97M | 2.21M | -5.92M | 4.89M | 7.39M | 6.74M | -14.6M | -14.99M |
| Pretax Income | -22.7M▲ 0% | -17.84M▲ 21.4% | -51.14M▼ 186.7% | 850K▲ 101.7% | -76.52M▼ 9102.6% | -61.23M▲ 20.0% | -68.79M▼ 12.4% | -54.66M▲ 0% |
| Pretax Margin % | -331.6% | -370.01% | -19082.09% | 1.9% | -9541.4% | -409.03% | - | - |
| Income Tax | 0 | 95K | -28K | -4.47M | -3.08M | -44K | -205K | -202K |
| Effective Tax Rate % | 0% | -0.53% | 0.05% | -526% | 4.02% | 0.07% | 0.3% | 0.37% |
| Net Income | -20.73M▲ 0% | -17.71M▲ 14.6% | -50.87M▼ 187.3% | 5.34M▲ 110.5% | -73.35M▼ 1473.0% | -61.07M▲ 16.7% | -66.43M▼ 8.8% | -52.31M▲ 0% |
| Net Margin % | -302.84% | -367.27% | -18979.48% | 11.95% | -9145.51% | -408% | - | - |
| Net Income Growth % | - | 14.59% | -187.28% | 110.5% | -1473.03% | 16.73% | -8.77% | 19.81% |
| Net Income (Continuing) | -22.7M | -17.93M | -51.11M | 5.32M | -73.45M | -61.18M | -66.43M | -52.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 367.19K | 391K | 437K | 305K | 211K | 106K | 84K | 79K |
| EPS (Diluted) | -436.87▲ 0% | -2.24▲ 99.5% | -1.37▲ 38.8% | 0.14▲ 110.2% | -1.91▼ 1464.3% | -1.55▲ 18.8% | -1.64▼ 5.8% | -1.28▲ 0% |
| EPS Growth % | - | 99.49% | 38.84% | 110.22% | -1464.29% | 18.85% | -5.81% | 21.34% |
| EPS (Basic) | -436.87 | -2.24 | -1.37 | 0.14 | -1.91 | -1.55 | -1.64 | - |
| Diluted Shares Outstanding | 7.82M | 7.9M | 37.19M | 38.17M | 38.39M | 39.35M | 40.53M | 40.85M |
| Basic Shares Outstanding | 7.82M | 7.9M | 37.19M | 37.25M | 38.39M | 39.35M | 40.53M | 40.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
BRNS Balance Sheet
Barinthus Biotherapeutics plc (BRNS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 16.25M | 47.9M | 226.76M | 213.04M | 156.91M | 125.74M | 77.79M | 72.66M |
| Cash & Short-Term Investments | 11.43M | 43.27M | 214.05M | 194.38M | 142.09M | 110.66M | 70.46M | 65.86M |
| Cash Only | 11.43M | 43.27M | 214.05M | 194.38M | 142.09M | 110.66M | 70.46M | 65.86M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.91M | 518K | 11.72M | 18.05M | 7.94M | 13M | 1.3M | 0 |
| Days Sales Outstanding | 208.38 | 39.22 | 15.96K | 147.34 | 3.61K | 316.94 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 3.04M | -3.62M | -5.28M | 1.47M | 2.08M | 6.03M | 6.81M |
| Total Non-Current Assets | 2.79M | 2.77M | 53.95M | 57.16M | 57.6M | 34.59M | 20.38M | 19.48M |
| Property, Plant & Equipment | 2.79M | 2.77M | 9.09M | 15.71M | 19.4M | 11.76M | 5.16M | 4.9M |
| Fixed Asset Turnover | 2.45x | 1.74x | 0.03x | 2.85x | 0.04x | 1.27x | - | 0.00x |
| Goodwill | 0 | 0 | 12.63M | 12.21M | 12.21M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 31.43M | 28.27M | 25.11M | 21.95M | 14.29M | 13.67M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 804K | 976K | 882K | 881K | 930K | 3.72M |
| Total Assets | 19.04M▲ 0% | 50.67M▲ 166.1% | 280.71M▲ 454.1% | 270.2M▼ 3.7% | 214.51M▼ 20.6% | 160.33M▼ 25.3% | 98.17M▼ 38.8% | 92.14M▲ 0% |
| Asset Turnover | 0.36x | 0.10x | 0.00x | 0.17x | 0.00x | 0.09x | - | 0.00x |
| Asset Growth % | - | 166.06% | 454.05% | -3.74% | -20.61% | -25.26% | -38.77% | -146.63% |
| Total Current Liabilities | 5.75M | 7.64M | 11.16M | 12.24M | 12.6M | 15.66M | 10.02M | 12M |
| Accounts Payable | 3.89M | 4.67M | 2.42M | 3.75M | 1.6M | 2.47M | 350K | 993K |
| Days Payables Outstanding | 47.56 | 118.4 | - | - | - | - | 21.81 | 386.14 |
| Short-Term Debt | 0 | 0 | 159K | 0 | 0 | 0 | 2.02M | 2M |
| Deferred Revenue (Current) | 269.91K | 0 | 182K | 0 | 0 | 1.74M | 1.4M | 3.24M |
| Other Current Liabilities | 373.89K | 245K | 1.42M | 1.93M | 6.01M | 1.77M | 6.25M | 8.69M |
| Current Ratio | 2.83x | 6.27x | 20.32x | 17.40x | 12.45x | 8.03x | 7.77x | 7.77x |
| Quick Ratio | 2.83x | 6.27x | 20.32x | 17.40x | 12.45x | 8.03x | 7.77x | 7.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 35.37M | 46.17M | 17M | 14.76M | 14.91M | 14.54M | 13.86M | 13.66M |
| Long-Term Debt | 0 | 44.7M | 0 | 0 | 0 | 0 | 0 | 9M |
| Capital Lease Obligations | 1.61M | 1.47M | 6.54M | 8.34M | 11.19M | 10.09M | 9.26M | 28.76M |
| Deferred Tax Liabilities | 0 | 0 | 8.08M | 3.75M | 574K | 438K | 254K | 882K |
| Other Non-Current Liabilities | 33.76M | 0 | 2.37M | 2.68M | 3.15M | 4.01M | 4.35M | 17.07M |
| Total Liabilities | 41.12M | 53.81M | 28.15M | 27M | 27.51M | 30.19M | 23.88M | 25.66M |
| Total Debt | 1.78M | 46.36M | 7.22M | 8.77M | 12.98M | 12.01M | 11.28M | 11.01M |
| Net Debt | -9.65M | 3.1M | -206.83M | -185.61M | -129.11M | -98.66M | -59.17M | -54.85M |
| Debt / Equity | - | - | 0.03x | 0.04x | 0.07x | 0.09x | 0.15x | 0.15x |
| Debt / EBITDA | - | - | - | 31.11x | - | - | - | -0.31x |
| Net Debt / EBITDA | - | - | - | -658.20x | - | - | - | 1.54x |
| Interest Coverage | -170.21x | -4.66x | -18.17x | 45.74x | -2731.93x | -1154.23x | -1060.16x | -1808.55x |
| Total Equity | -22.08M▲ 0% | -3.15M▲ 85.7% | 252.56M▲ 8125.5% | 243.2M▼ 3.7% | 187M▼ 23.1% | 130.13M▼ 30.4% | 74.29M▼ 42.9% | 66.48M▲ 0% |
| Equity Growth % | - | 85.75% | 8125.48% | -3.71% | -23.11% | -30.41% | -42.91% | -167.01% |
| Book Value per Share | -2.82 | -0.40 | 6.79 | 6.37 | 4.87 | 3.31 | 1.83 | 1.63 |
| Total Shareholders' Equity | -22.45M | -3.54M | 252.13M | 242.9M | 186.78M | 130.03M | 74.21M | 66.4M |
| Common Stock | 330 | 0 | 1K | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -37.89M | -57.72M | -108.58M | -103.24M | -176.59M | -237.66M | -304.09M | -309.63M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -467.36K | -1.24M | -8.49M | -33.46M | -23.32M | -25.87M | -15.73M | -18.56M |
| Minority Interest | 367.19K | 391K | 437K | 305K | 211K | 106K | 84K | 79K |
BRNS Cash Flow Statement
Barinthus Biotherapeutics plc (BRNS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.76M | -11.03M | -32.58M | -14.43M | -50.92M | -28.94M | -47.98M | -47.98M |
| Operating CF Margin % | -274.06% | -228.75% | -12157.84% | -32.28% | -6349.75% | -193.33% | - | - |
| Operating CF Growth % | - | 41.21% | -195.46% | 55.71% | -252.89% | 43.17% | -65.79% | -64.43% |
| Net Income | -20.82M | -17.93M | -51.11M | 5.32M | -73.45M | -61.18M | -66.46M | -52.31M |
| Depreciation & Amortization | 346.86K | 208K | 602K | 4.32M | 5.43M | 5.8M | 5.84M | 4.67M |
| Stock-Based Compensation | 0 | 3.63M | 16.49M | 9.88M | 5.05M | 4.71M | 468K | -140K |
| Deferred Taxes | 0 | 0 | -119K | -4.34M | -3.08M | -44K | -175K | -168.98K |
| Other Non-Cash Items | -1.23M | 1.15M | 8.74M | -24.09M | 8.94M | 19.18M | 12.7M | 11.76M |
| Working Capital Changes | 2.94M | 1.92M | -7.18M | -5.52M | 6.17M | 2.6M | -359.84K | -209.16K |
| Change in Receivables | -963.16K | 774K | -3.05M | -4.67M | 5.67M | -2.35M | 6.42M | 2.17M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.98M | 586K | -3.53M | 1.14M | -3.38M | 898K | -2.2M | -401.47K |
| Cash from Investing | 1.93M | -293K | -12.91M | -5.75M | -5.41M | -892K | 416K | 475.48K |
| Capital Expenditures | -128.35K | -293K | -1.15M | -6.14M | -5.41M | -892K | -37K | 419.05K |
| CapEx % of Revenue | 1.88% | 6.08% | 427.61% | 13.73% | 674.94% | 5.96% | - | - |
| Acquisitions | 2.06M | 0 | -11.77M | 0 | 0 | 0 | 454.06K | 1.43K |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 388K | 0 | 0 | -1.06K | 55K |
| Cash from Financing | 1 | 41.44M | 222.74M | 325K | 1.87M | 2.16M | 2K | 0 |
| Debt Issued (Net) | 0 | 41.24M | 0 | -159K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1 | 0 | 228.01M | 484K | 2.04M | 2.16M | 2K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 194K | -5.27M | 0 | -163K | 0 | -4 | 0 |
| Net Change in Cash | 11.43M▲ 0% | 31.83M▲ 178.5% | 170.79M▲ 436.5% | -19.67M▼ 111.5% | -52.3M▼ 165.9% | -29.69M▲ 43.2% | -40.55M▼ 36.6% | -33.39M▲ 0% |
| Free Cash Flow | -18.89M▲ 0% | -11.32M▲ 40.1% | -33.73M▼ 197.9% | -20.57M▲ 39.0% | -56.34M▼ 173.9% | -29.83M▲ 47.0% | -48.02M▼ 61.0% | -36.43M▲ 0% |
| FCF Margin % | -275.93% | -234.83% | -12585.45% | -46.01% | -7024.69% | -199.29% | - | - |
| FCF Growth % | - | 40.06% | -197.93% | 39.02% | -173.9% | 47.05% | -60.95% | -11.72% |
| FCF per Share | -2.42 | -1.43 | -0.91 | -0.54 | -1.47 | -0.76 | -1.18 | -1.18 |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.62x | 0.64x | -2.70x | 0.69x | 0.47x | 0.72x | 0.70x |
| Interest Paid | 0 | 2K | 1.84M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 152K | 0 | 0 | 0 | 0 | 0 |
BRNS Key Ratios
Barinthus Biotherapeutics plc (BRNS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -40.79% | 2.16% | -34.1% | -38.52% | -64.99% | -63.83% |
| Return on Invested Capital (ROIC) | - | -148.49% | -5.87% | -109.01% | -114.09% | -174.46% | -174.46% |
| Gross Margin | -198.42% | 100% | 100% | 100% | 100% | - | - |
| Net Margin | -367.27% | -18979.48% | 11.95% | -9145.51% | -408% | - | - |
| Debt / Equity | - | 0.03x | 0.04x | 0.07x | 0.09x | 0.15x | 0.15x |
| Interest Coverage | -4.66x | -18.17x | 45.74x | -2731.93x | -1154.23x | -1060.16x | -1808.55x |
| FCF Conversion | 0.62x | 0.64x | -2.70x | 0.69x | 0.47x | 0.72x | 0.70x |
| Revenue Growth | -29.57% | -94.44% | 16580.22% | -98.21% | 1766.46% | -100% | -100% |
BRNS SEC Filings & Documents
Barinthus Biotherapeutics plc (BRNS) SEC filings — annual & quarterly reports (10-K, 10-Q)
BRNS Frequently Asked Questions
Barinthus Biotherapeutics plc (BRNS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Barinthus Biotherapeutics plc (BRNS) saw revenue decline by 100.0% over the past year.
Barinthus Biotherapeutics plc (BRNS) reported a net loss of $52.3M for fiscal year 2025.
Dividend & Returns
Barinthus Biotherapeutics plc (BRNS) has a return on equity (ROE) of -65.0%. Negative ROE indicates the company is unprofitable.
Barinthus Biotherapeutics plc (BRNS) had negative free cash flow of $36.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More BRNS
Barinthus Biotherapeutics plc (BRNS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates